{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T01:12:26Z","timestamp":1790730746414,"version":"4.1.0"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Immunology"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.coi.2026.102803","type":"journal-article","created":{"date-parts":[[2026,6,14]],"date-time":"2026-06-14T15:58:11Z","timestamp":1781452691000},"page":"102803","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Raynaud\u2019s phenomenon: a vascular or an autoimmune-mediated disorder? Facts and fancy"],"prefix":"10.1016","volume":"101","author":[{"given":"Haralampos M","family":"Moutsopoulos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilir I","family":"Cinoku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clio P","family":"Mavragani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.coi.2026.102803_bib1","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1177\/096777209700500110","article-title":"Maurice R Raynaud and his protean disease","volume":"5","author":"Andrews","year":"1997","journal-title":"J Med Biogr"},{"key":"10.1016\/j.coi.2026.102803_bib2","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1056\/NEJMra1507638","article-title":"Raynaud\u2019s phenomenon","volume":"375","author":"Wigley","year":"2016","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.coi.2026.102803_bib3","first-page":"243","article-title":"Subclinical manifestations of autoimmune rheumatic diseases in primary Raynaud\u2019s phenomenon","volume":"3","author":"Tzioufas","year":"1985","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.coi.2026.102803_bib4","first-page":"756","article-title":"The clinical significance of Raynaud\u2019s syndrome","volume":"80","author":"Porter","year":"1976","journal-title":"Surgery"},{"key":"10.1016\/j.coi.2026.102803_bib5","doi-asserted-by":"crossref","DOI":"10.1001\/archinte.158.6.595","article-title":"Outcomes in primary Raynaud phenomenon","volume":"158","author":"Spencer-Green","year":"1998","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.coi.2026.102803_bib6","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/art.1780280114","article-title":"Evolution of primary Raynaud\u2019s phenomenon (Raynaud\u2019s disease) to connective tissue disease","volume":"28","author":"Gerbracht","year":"1985","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.coi.2026.102803_bib7","series-title":"Immunology and Rheumatology in Questions","first-page":"77","author":"Moutsopoulos","year":"2021"},{"key":"10.1016\/j.coi.2026.102803_bib8","doi-asserted-by":"crossref","first-page":"279","DOI":"10.3899\/jrheum.180355","article-title":"Nailfold capillaroscopy characteristics of antisynthetase syndrome and possible clinical associations: results of a multicenter international study","volume":"46","author":"Sebastiani","year":"2019","journal-title":"J Rheumatol"},{"key":"10.1016\/j.coi.2026.102803_bib9","first-page":"618","article-title":"Raynaud\u2019s phenomenon in primary Sj\u00f6gren\u2019s syndrome","volume":"17","author":"Skopouli","year":"1990","journal-title":"J Rheumatol"},{"key":"10.1016\/j.coi.2026.102803_bib10","doi-asserted-by":"crossref","first-page":"3902","DOI":"10.1002\/art.24038","article-title":"Autoantibodies and microvascular damage are independent predictive factors for the progression of Raynaud\u2019s phenomenon to systemic sclerosis: a twenty-year prospective study of 586 patients, with validation of proposed criteria for early systemic sclerosis","volume":"58","author":"Koenig","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.coi.2026.102803_bib11","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1093\/rheumatology\/key026","article-title":"The patient experience of Raynaud\u2019s phenomenon in systemic sclerosis","volume":"58","author":"Pauling","year":"2019","journal-title":"Rheumatology"},{"key":"10.1016\/j.coi.2026.102803_bib12","first-page":"117","article-title":"Infections of scleroderma digital ulcers: a single center cohort retrospective study","volume":"13","author":"Giuggioli","year":"2021","journal-title":"Dermatol Rep"},{"key":"10.1016\/j.coi.2026.102803_bib13","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1002\/art.1780220802","article-title":"The clinical significance of Raynaud\u2019s phenomenon in systemic lupus erythematosus","volume":"22","author":"Dimant","year":"1979","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.coi.2026.102803_bib14","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1007\/s10067-011-1727-0","article-title":"The association of Raynaud\u2019s syndrome with rheumatoid arthritis \u2013 a meta-analysis","volume":"30","author":"Hartmann","year":"2011","journal-title":"Clin Rheumatol"},{"issue":"1","key":"10.1016\/j.coi.2026.102803_bib15","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/bcp.12912","article-title":"Drug-induced Raynaud\u2019s phenomenon: beyond \u03b2-adrenoceptor blockers","volume":"82","author":"Khouri","year":"2016","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.coi.2026.102803_bib16","doi-asserted-by":"crossref","first-page":"658","DOI":"10.12968\/hmed.2019.80.11.658","article-title":"Raynaud\u2019s phenomenon","volume":"80","author":"Devgire","year":"2019","journal-title":"Br J Hosp Med"},{"key":"10.1016\/j.coi.2026.102803_bib17","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.amsu.2016.03.028","article-title":"Thromboangiitis obliterans (Buerger\u2019s disease)","volume":"7","author":"Rivera-Chavarr\u00eda","year":"2016","journal-title":"Ann Med Surg"},{"key":"10.1016\/j.coi.2026.102803_bib18","doi-asserted-by":"crossref","first-page":"417","DOI":"10.4103\/0019-5154.119946","article-title":"Acrocyanosis: an overview","volume":"58","author":"Das","year":"2013","journal-title":"Indian J Dermatol"},{"key":"10.1016\/j.coi.2026.102803_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102458","article-title":"Standardisation of nailfold capillaroscopy for the assessment of patients with Raynaud\u2019s phenomenon and systemic sclerosis","volume":"19","author":"Smith","year":"2020","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.coi.2026.102803_bib20","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1093\/rheumatology\/38.9.826","article-title":"Microvascular abnormalities in Sjogren\u2019s syndrome: nailfold capillaroscopy","volume":"38","author":"Tektonidou","year":"1999","journal-title":"Rheumatology"},{"key":"10.1016\/j.coi.2026.102803_bib21","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1007\/s10067-024-06879-7","article-title":"Naifold capillaroscopy in mixed connective tissue disease patients","volume":"43","author":"Ornowska","year":"2024","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.coi.2026.102803_bib22","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.autrev.2017.11.025","article-title":"Nailfold capillaroscopy in systemic lupus erythematosus: a systematic review and critical appraisal","volume":"17","author":"Cutolo","year":"2018","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.coi.2026.102803_bib23","first-page":"S150","article-title":"Nailfold capillaroscopy in Sj\u00f6gren\u2019s syndrome: a systematic literature review and standardised interpretation","volume":"38","author":"Melsens","year":"2021","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.coi.2026.102803_bib24","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1152\/japplphysiol.00407.2010","article-title":"Local thermal control of the human cutaneous circulation","volume":"109","author":"Johnson","year":"2010","journal-title":"J Appl Physiol"},{"key":"10.1016\/j.coi.2026.102803_bib25","first-page":"146","article-title":"A vascular mechanistic approach to understanding Raynaud phenomenon","volume":"11","author":"Flavahan","year":"2015","journal-title":"Nat Publ Gr"},{"key":"10.1016\/j.coi.2026.102803_bib26","doi-asserted-by":"crossref","first-page":"28S","DOI":"10.1016\/0895-7061(95)00030-S","article-title":"Endothelial cell signaling and endothelial dysfunction","volume":"8","author":"Flavahan","year":"1995","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.coi.2026.102803_sbref27","article-title":"\u03b12 adrenoceptors, cold-induced vasoconstriction, and Raynaud\u2019s phenomenon","volume":"5","author":"Flavahan","year":"2025","journal-title":"Cell Genom"},{"key":"10.1016\/j.coi.2026.102803_bib28","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.bbamem.2006.11.001","article-title":"Seven transmembrane receptors \u2013 a brief personal retrospective","volume":"1768","author":"Lefkowitz","year":"2007","journal-title":"Biochim Biophys Acta \u2013 Biomembr"},{"key":"10.1016\/j.coi.2026.102803_sbref29","doi-asserted-by":"crossref","first-page":"eabj5347","DOI":"10.1126\/sciadv.abj5347","article-title":"Structural insights into ligand recognition, activation, and signaling of the \u03b12A adrenergic receptor","volume":"8","author":"Xu","year":"2022","journal-title":"Sci Adv"},{"issue":"1","key":"10.1016\/j.coi.2026.102803_bib30","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1002\/anr.1780320110","article-title":"Increased alpha-adrenergic responsiveness in idiopathic Raynaud's disease","volume":"32","author":"Freedman","year":"1989","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.coi.2026.102803_bib31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13075-020-02360-3","article-title":"Scleroderma-specific autoantibodies embedded in immune complexes mediate endothelial damage: an early event in the pathogenesis of systemic sclerosis","volume":"22","author":"Raschi","year":"2020","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.coi.2026.102803_bib32","first-page":"38","article-title":"\u03b12-Adrenergic receptor levels in obstructive and spastic Raynaud\u2019s syndrome","volume":"5","author":"Edwards","year":"1987","journal-title":"J Vasc Surg"},{"key":"10.1016\/j.coi.2026.102803_bib33","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1038\/nrrheum.2017.134","article-title":"Functional autoantibodies targeting G protein-coupled receptors in rheumatic diseases","volume":"13","author":"Cabral-Marques","year":"2017","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.coi.2026.102803_bib34","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1136\/ard.2010.135772","article-title":"Involvement of functional autoantibodies against vascular receptors in systemic sclerosis","volume":"70","author":"Riemekasten","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coi.2026.102803_bib35","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1161\/HYPERTENSIONAHA.111.171348","article-title":"Angiotensin II type 1 receptor antibodies and increased angiotensin II sensitivity in pregnant rats","volume":"58","author":"Wenzel","year":"2011","journal-title":"Hypertension"},{"key":"10.1016\/j.coi.2026.102803_bib36","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.2741\/4691","article-title":"Role of alpha1-adrenergic receptor antibodies in Alzheimer\u2019s disease","volume":"23","author":"Karczewski","year":"2018","journal-title":"Front Biosci (Landmark Ed)"},{"issue":"1","key":"10.1016\/j.coi.2026.102803_sbref37","doi-asserted-by":"crossref","first-page":"6156","DOI":"10.1038\/s41467-023-41876-5","article-title":"ADRA2A and IRX1 are putative risk genes for Raynaud\u2019s phenomenon","volume":"14","author":"Hartmann","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.coi.2026.102803_sbref38","article-title":"Novel pleiotropic loci links vascular and immune pathways in systemic sclerosis and primary Raynaud\u2019s phenomenon","volume":"8","author":"Rangel-Pel\u00e1ez","year":"2026","journal-title":"Rheumatology"},{"key":"10.1016\/j.coi.2026.102803_bib39","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/keag121.171","article-title":"The Role of the IRX1 Gene Variant rs12653958 in Late-onset Raynaud\u2019s Phenomenon","volume":"65","author":"Karampela","year":"2026","journal-title":"Rheumatology"},{"key":"10.1016\/j.coi.2026.102803_sbref40","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1097\/BOR.0000000000000877","article-title":"Practical management of Raynaud\u2019s phenomenon \u2013 a primer for practicing physicians","volume":"34","author":"Ramahi","year":"2022","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.coi.2026.102803_bib41","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1111\/bcp.14322","article-title":"Drug repurposing in Raynaud\u2019s phenomenon through adverse event signature matching in the World Health Organization pharmacovigilance database","volume":"86","author":"Zaza","year":"2020","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.coi.2026.102803_bib42","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1007\/s00296-020-04606-4","article-title":"Targeted high concentration botulinum toxin A injections in patients with Raynaud\u2019s phenomenon: a retrospective single-centre experience","volume":"41","author":"Nagarajan","year":"2021","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.coi.2026.102803_bib43","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1161\/01.CIR.92.6.1448","article-title":"Blockade of vasospastic attacks by \u03b12-adrenergic but not \u03b11-adrenergic antagonists in idiopathic Raynaud\u2019s disease","volume":"92","author":"Freedman","year":"1995","journal-title":"Circulation"},{"key":"10.1016\/j.coi.2026.102803_bib44","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1152\/ajpheart.2000.278.4.H1075","article-title":"Silent \u03b1(2C)-adrenergic receptors enable cold-induced vasoconstriction in cutaneous arteries","volume":"278","author":"Chotani","year":"2000","journal-title":"Am J Physiol \u2013 Hear Circ Physiol"},{"key":"10.1016\/j.coi.2026.102803_bib45","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1093\/rheumatology\/ket421","article-title":"A double-blind, randomized, placebo-controlled crossover trial of the \u03b12C-adrenoceptor antagonist ORM-12741 for prevention of cold-induced vasospasm in patients with systemic sclerosis","volume":"53","author":"Herrick","year":"2014","journal-title":"Rheumatology"},{"key":"10.1016\/j.coi.2026.102803_bib46","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1016\/j.bbamcr.2011.05.006","article-title":"Intracellular \u03b12C-adrenoceptors: storage depot, stunted development or signaling domain?","volume":"1813","author":"Chotani","year":"2011","journal-title":"Biochim Biophys Acta \u2013 Mol Cell Res"},{"issue":"2","key":"10.1016\/j.coi.2026.102803_bib47","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1024\/0301-1526\/a000675","article-title":"Erythromelalgia","volume":"47","author":"Klein-Weigel","year":"2018","journal-title":"Vasa."}],"container-title":["Current Opinion in Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0952791526000804?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0952791526000804?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T08:40:44Z","timestamp":1783932044000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0952791526000804"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":47,"alternative-id":["S0952791526000804"],"URL":"https:\/\/doi.org\/10.1016\/j.coi.2026.102803","relation":{},"ISSN":["0952-7915"],"issn-type":[{"value":"0952-7915","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Raynaud\u2019s phenomenon: a vascular or an autoimmune-mediated disorder? Facts and fancy","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coi.2026.102803","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102803"}}